Back to results
US 2024/0402180 A1Published application
Metabolite biomarkers for differential diagnosis of pacreatic cysts
AssigneeThe Regents of the University of Michigan
InventorJiaqi Shi
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for identifying early-stage pancreatic cancer in a subject. The methods are based, in part, on the change of metabolic biomarker levels indicative of malignant or mucinous pancreatic cysts which can be used for prognostic classification.
Claims25
A method for treating or selecting a treatment for a subject at risk of or having a pancreatic disease or disorder, comprising:
- determining or having determined an amount of at least one metabolic biomarker in a biological sample from the subject;
- performing a comparison or having performed a comparison of the amount of the at least one metabolic biomarker in the biological sample to a reference for a subject not having the pancreatic disease or disorder, wherein presence of a change in amount of the at least one metabolic biomarker is associated with presence of the pancreatic disease or disorder or increased risk of developing the pancreatic disease or disorder;
- selecting a treatment based on the comparison;
- and
- administering an effective amount of the treatment when the comparison indicates the subject has or is at increased risk for the pancreatic disease or disorder, wherein the at least one metabolic biomarker comprises 5-oxoproline.
2 more elements
3-5. (canceled)
(canceled)
(canceled)
16-17. (canceled)
A method comprising:
- determining an amount of at least one metabolic biomarker in a pancreatic tissue or pancreatic juices or fluids sample from a subject, wherein the at least one metabolic biomarker is 5-oxoproline.
28-46. (canceled)
Dependencies are inferred from the claim text.